Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose finding trials.

Lyu J, Ji Y, Zhao N, Catenacci DVT.

J R Stat Soc Ser C Appl Stat. 2019 Feb;68(2):385-410. doi: 10.1111/rssc.12291. Epub 2018 Jun 13.

2.

Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?

Lin D, Khan U, Goetze TO, Reizine N, Goodman KA, Shah MA, Catenacci DV, Al-Batran SE, Posey JA.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:e88-e95. doi: 10.1200/EDBK_236827. Epub 2019 May 17.

PMID:
31099690
3.

Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase 3 study design.

Catenacci DV, Tesfaye A, Tejani M, Cheung E, Eisenberg P, Scott AJ, Eng C, Hnatyszyn J, Marina N, Powers J, Wainberg Z.

Future Oncol. 2019 May 16. doi: 10.2217/fon-2019-0141. [Epub ahead of print]

4.

Keeping Checkpoint Inhibitors in Check.

Catenacci DVT, Hochster H, Klempner SJ.

JAMA Netw Open. 2019 May 3;2(5):e192546. doi: 10.1001/jamanetworkopen.2019.2546. No abstract available.

PMID:
31050772
5.

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.

Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB.

Oncologist. 2019 Apr 30. pii: theoncologist.2019-0034. doi: 10.1634/theoncologist.2019-0034. [Epub ahead of print]

PMID:
31040255
6.

When Inhibitor MET Biomarker: Postmortem or Initium Novum?

Catenacci DVT.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00359. Epub 2019 Mar 8. No abstract available.

7.

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.

Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC.

Gastric Cancer. 2019 Jul;22(4):828-837. doi: 10.1007/s10120-018-00909-5. Epub 2019 Mar 25.

PMID:
30911859
8.

Variety Is the Spice of Life, but Maybe Not in Gastroesophageal Adenocarcinomas.

Klempner SJ, Catenacci DVT.

Cancer Discov. 2019 Feb;9(2):166-168. doi: 10.1158/2159-8290.CD-18-1447.

PMID:
30737213
9.

A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.

Sharma MR, Joshi SS, Karrison TG, Allen K, Suh G, Marsh R, Kozloff MF, Polite BN, Catenacci DVT, Kindler HL.

Cancer. 2019 May 15;125(10):1629-1636. doi: 10.1002/cncr.31938. Epub 2019 Jan 15.

PMID:
30645764
10.

Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.

Klempner SJ, Maron SB, Chase L, Lomnicki S, Wainberg ZA, Catenacci DVT.

Oncologist. 2019 Apr;24(4):475-482. doi: 10.1634/theoncologist.2018-0602. Epub 2018 Nov 23.

PMID:
30470690
11.

Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors.

Hong DS, LoRusso P, Hamid O, Janku F, Kittaneh M, Catenacci DVT, Chan E, Bekaii-Saab T, Gadgeel SM, Loberg RD, Amore BM, Hwang YC, Tang R, Ngarmchamnanrith G, Kwak EL.

Clin Cancer Res. 2019 Apr 15;25(8):2403-2413. doi: 10.1158/1078-0432.CCR-18-1341. Epub 2018 Nov 13.

PMID:
30425090
12.

Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial.

Dahdaleh FS, Sherman SK, Poli EC, Vigneswaran J, Polite BN, Sharma MR, Catenacci DV, Maron SB, Turaga KK.

Surgery. 2018 Dec;164(6):1223-1229. doi: 10.1016/j.surg.2018.06.044. Epub 2018 Oct 5.

PMID:
30297240
13.

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.

Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH.

JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013. Epub 2018 May 10.

14.

Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma.

Maron SB, Alpert L, Kwak HA, Lomnicki S, Chase L, Xu D, O'Day E, Nagy RJ, Lanman RB, Cecchi F, Hembrough T, Schrock A, Hart J, Xiao SY, Setia N, Catenacci DVT.

Cancer Discov. 2018 Jun;8(6):696-713. doi: 10.1158/2159-8290.CD-17-1260. Epub 2018 Feb 15.

15.

Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.

Joshi SS, Maron SB, Catenacci DV.

Future Oncol. 2018 Feb;14(5):417-430. doi: 10.2217/fon-2017-0436. Epub 2017 Nov 2. Review.

16.

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.

Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV.

Cancer Discov. 2018 Jan;8(1):37-48. doi: 10.1158/2159-8290.CD-17-0395. Epub 2017 Oct 4.

17.

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe M, De Vita F, Turkington C, Tang R, Ang A, Zhang Y, Hoang T, Sidhu R, Cunningham D.

Lancet Oncol. 2017 Nov;18(11):1467-1482. doi: 10.1016/S1470-2045(17)30566-1. Epub 2017 Sep 25.

18.

Update on Gastroesophageal Adenocarcinoma Targeted Therapies.

Maron SB, Catenacci DVT.

Hematol Oncol Clin North Am. 2017 Jun;31(3):511-527. doi: 10.1016/j.hoc.2017.01.009. Review.

19.

Novel Targeted Therapies for Esophagogastric Cancer.

Maron SB, Catenacci DV.

Surg Oncol Clin N Am. 2017 Apr;26(2):293-312. doi: 10.1016/j.soc.2016.10.002. Review.

20.

It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma.

Elimova E, Janjigian YY, Mulcahy M, Catenacci DV, Blum MA, Almhanna K, Hecht JR, Ajani JA.

J Clin Oncol. 2017 Feb;35(4):475-477. doi: 10.1200/JCO.2016.69.7276. Epub 2016 Oct 28. No abstract available.

PMID:
28129519
21.

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.

Catenacci DV, Ang A, Liao WL, Shen J, O'Day E, Loberg RD, Cecchi F, Hembrough T, Ruzzo A, Graziano F.

Cancer. 2017 May 15;123(6):1061-1070. doi: 10.1002/cncr.30437. Epub 2016 Dec 7.

22.

A subgroup cluster-based Bayesian adaptive design for precision medicine.

Guo W, Ji Y, Catenacci DVT.

Biometrics. 2017 Jun;73(2):367-377. doi: 10.1111/biom.12613. Epub 2016 Oct 24.

23.

Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.

An E, Ock CY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Liao WL, Cecchi F, Blackler A, Thyparambil S, Kim WH, Burrows J, Hembrough T, Catenacci DVT, Oh DY, Bang YJ.

Ann Oncol. 2017 Jan 1;28(1):110-115. doi: 10.1093/annonc/mdw442.

24.

Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance.

Sellappan S, Blackler A, Liao WL, O'Day E, Xu P, Thyparambil S, Cecchi F, Hembrough T, Catenacci DV.

J Natl Compr Canc Netw. 2016 May;14(5):503-7.

25.

A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers.

Coveler AL, Ko AH, Catenacci DV, Von Hoff D, Becerra C, Whiting NC, Yang J, Wolpin B.

Invest New Drugs. 2016 Jun;34(3):319-28. doi: 10.1007/s10637-016-0343-x. Epub 2016 Mar 18.

PMID:
26994014
26.

How can next-generation diagnostics aid pancreatic adenocarcinoma treatment?

Zhang SQ, Catenacci DV.

Future Oncol. 2016 Mar;12(5):585-8. doi: 10.2217/fon.15.353. Epub 2016 Feb 2. No abstract available.

27.

Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH.

Catenacci DVT, Liao WL, Zhao L, Whitcomb E, Henderson L, O'Day E, Xu P, Thyparambil S, Krizman D, Bengali K, Uzzell J, Darfler M, Cecchi F, Blackler A, Bang YJ, Hart J, Xiao SY, Lee SM, Burrows J, Hembrough T.

Gastric Cancer. 2016 Oct;19(4):1066-1079. doi: 10.1007/s10120-015-0566-0. Epub 2015 Nov 18.

28.

Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution.

Ling S, Hu Z, Yang Z, Yang F, Li Y, Lin P, Chen K, Dong L, Cao L, Tao Y, Hao L, Chen Q, Gong Q, Wu D, Li W, Zhao W, Tian X, Hao C, Hungate EA, Catenacci DV, Hudson RR, Li WH, Lu X, Wu CI.

Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6496-505. doi: 10.1073/pnas.1519556112. Epub 2015 Nov 11. Erratum in: Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):E663.

29.

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.

Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL.

J Clin Oncol. 2015 Dec 20;33(36):4284-92. doi: 10.1200/JCO.2015.62.8719. Epub 2015 Nov 2.

30.

A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.

Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL.

Pancreas. 2016 Mar;45(3):370-5. doi: 10.1097/MPA.0000000000000458.

31.

Expansion platform type II: testing a treatment strategy.

Catenacci DV.

Lancet Oncol. 2015 Oct;16(13):1276-8. doi: 10.1016/S1470-2045(15)00224-7. Epub 2015 Sep 3. No abstract available.

32.

Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound.

Catenacci DV, Chapman CG, Xu P, Koons A, Konda VJ, Siddiqui UD, Waxman I.

Gastroenterology. 2015 Dec;149(7):1794-1803.e4. doi: 10.1053/j.gastro.2015.08.050. Epub 2015 Sep 2.

33.

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

Ali SM, Sanford EM, Klempner SJ, Rubinson DA, Wang K, Palma NA, Chmielecki J, Yelensky R, Palmer GA, Morosini D, Lipson D, Catenacci DV, Braiteh F, Erlich R, Stephens PJ, Ross JS, Ou SH, Miller VA.

Oncologist. 2015 May;20(5):499-507. doi: 10.1634/theoncologist.2014-0378. Epub 2015 Apr 16.

34.

Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.

Catenacci DV.

Mol Oncol. 2015 May;9(5):967-96. doi: 10.1016/j.molonc.2014.09.011. Epub 2014 Oct 18. Review.

35.

Next-generation companion diagnostics: promises, challenges, and solutions.

Khoury JD, Catenacci DV.

Arch Pathol Lab Med. 2015 Jan;139(1):11-3. doi: 10.5858/arpa.2014-0063-ED. No abstract available.

36.

Tumor genome analysis includes germline genome: are we ready for surprises?

Catenacci DV, Amico AL, Nielsen SM, Geynisman DM, Rambo B, Carey GB, Gulden C, Fackenthal J, Marsh RD, Kindler HL, Olopade OI.

Int J Cancer. 2015 Apr 1;136(7):1559-67. doi: 10.1002/ijc.29128. Epub 2014 Aug 14.

37.

Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue.

Catenacci DV, Liao WL, Thyparambil S, Henderson L, Xu P, Zhao L, Rambo B, Hart J, Xiao SY, Bengali K, Uzzell J, Darfler M, Krizman DB, Cecchi F, Bottaro DP, Karrison T, Veenstra TD, Hembrough T, Burrows J.

PLoS One. 2014 Jul 1;9(7):e100586. doi: 10.1371/journal.pone.0100586. eCollection 2014.

38.

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.

Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, Lee HJ, Sheehan CE, Otto GA, Palmer G, Yelensky R, Lipson D, Morosini D, Hawryluk M, Catenacci DV, Miller VA, Churi C, Ali S, Stephens PJ.

Oncologist. 2014 Mar;19(3):235-42. doi: 10.1634/theoncologist.2013-0352. Epub 2014 Feb 21.

39.

Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.

Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, Bai S, Kaur S, Nijem I, Catenacci DV, Peterson A, Ratain MJ, Polite B, Mehnert JM, Moss RA.

Clin Cancer Res. 2014 Mar 15;20(6):1666-75. doi: 10.1158/1078-0432.CCR-13-2070. Epub 2014 Feb 3.

40.

Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care.

Sehdev A, Catenacci DV.

J Hematol Oncol. 2013 Sep 5;6:66. doi: 10.1186/1756-8722-6-66. Review.

41.

Gastroesophageal cancer: focus on epidemiology, classification, and staging.

Sehdev A, Catenacci DV.

Discov Med. 2013 Sep;16(87):103-11. Review.

42.

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.

Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP.

PLoS One. 2013;8(3):e54014. doi: 10.1371/journal.pone.0054014. Epub 2013 Mar 14.

43.

A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma.

Geynisman DM, Zha Y, Kunnavakkam R, Aklilu M, Catenacci DV, Polite BN, Rosenbaum C, Namakydoust A, Karrison T, Gajewski TF, Kindler HL.

J Immunother Cancer. 2013 Jun 27;1:8. doi: 10.1186/2051-1426-1-8. eCollection 2013.

44.

Toward personalized treatment of advanced biliary tract cancers.

Geynisman DM, Catenacci DV.

Discov Med. 2012 Jul;14(74):41-57. Review.

45.

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.

Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, Hegde P, Zha J, Pandita A, Peterson A, Salgia R.

Cancer Discov. 2011 Dec;1(7):573-9. doi: 10.1158/2159-8290.CD-11-0175.

46.

RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.

Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, Bang YJ, Kim WH, Tretiakova M, Vokes E, Frank DA, Kindler HL, Huet H, Salgia R.

Cancer Biol Ther. 2011 Jul 1;12(1):9-46. doi: 10.4161/cbt.12.1.15747. Epub 2011 Jul 1.

47.

Personalized colon cancer care in 2010.

Catenacci DV, Kozloff M, Kindler HL, Polite B.

Semin Oncol. 2011 Apr;38(2):284-308. doi: 10.1053/j.seminoncol.2011.01.001. Review.

48.

Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic.

Stricker T, Catenacci DV, Seiwert TY.

Semin Oncol. 2011 Apr;38(2):173-85. doi: 10.1053/j.seminoncol.2011.01.013. Review.

PMID:
21421108
49.

A survey of the population genetic variation in the human kinome.

Zhang W, Catenacci DV, Duan S, Ratain MJ.

J Hum Genet. 2009 Aug;54(8):488-92. doi: 10.1038/jhg.2009.72. Epub 2009 Jul 31.

50.

Myelodysplasic syndromes: a comprehensive review.

Catenacci DV, Schiller GJ.

Blood Rev. 2005 Nov;19(6):301-19. Review.

PMID:
15885860

Supplemental Content

Loading ...
Support Center